Personalis Inc
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(15,750) | $(12,968) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 2,219 | 2,687 |
| Depreciation and amortization | 2,587 | 2,837 |
| Noncash operating lease cost | 398 | 337 |
| Noncash gain related to liability classified Tempus Warrants | — | (4,765) |
| Amortization of discount on short-term investments | (1,084) | (723) |
| Other | (377) | 199 |
| Changes in operating assets and liabilities | ||
| Accounts receivable (1) | (2,833) | 6,385 |
| Inventory and other deferred costs | 1,017 | 1,707 |
| Prepaid expenses and other assets | (1,230) | (203) |
| Accounts payable (2) | 2,013 | (5,637) |
| Accrued and other current liabilities (2) | (2,742) | (7,836) |
| Contract liabilities | (1,136) | (1,593) |
| Operating lease liabilities | (993) | (840) |
| Other long-term liabilities (2) | (50) | — |
| Net cash used in operating activities | (17,961) | (20,413) |
| Cash flows from investing activities: | ||
| Purchases of available-for-sale debt securities | (64,281) | (29,095) |
| Proceeds from maturities of available-for-sale debt securities | 44,250 | 35,500 |
| Purchases of property and equipment | (2,511) | (104) |
| Net cash (used in) provided by investing activities | (22,542) | 6,301 |
| Cash flows from financing activities: | ||
| Proceeds from sales of common stock under ATM facility, net of commissions | 17,782 | 1,437 |
| Payment of costs related to Tempus and Merck Investment Agreements | (106) | — |
| Proceeds from loans | 2,587 | — |
| Repayments of loans | (308) | (308) |
| Proceeds from issuance of common stock under equity incentive plans | 132 | — |
| Net cash provided by financing activities | 20,087 | 1,129 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 2 | (20) |
| Net change in cash, cash equivalents and restricted cash | (20,414) | (13,003) |
| Cash, cash equivalents and restricted cash, beginning of period | 93,205 | 58,774 |
| Cash, cash equivalents and restricted cash, end of period | $72,791 | $45,771 |
| Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: | ||
| Cash and cash equivalents | $71,001 | $43,981 |
| Restricted cash, included in other long-term assets | 1,790 | 1,790 |
| Total cash, cash equivalents and restricted cash | $72,791 | $45,771 |
(1) Includes a change in related party receivable of $1.9 million for the three months ended March 31, 2025.
(2) Includes a change in related party liabilities of $1.0 million for the three months ended March 31, 2025.
See Notes to the Consolidated Financial Statements.
PERSONALIS, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.